Approximately one million HIV-infected children live in the 47 countries with the highest burden of measles [1, 2] . Measles occurs at a younger age and is associated with an increased risk of severe illness and death in HIV-infected children [3, 4] . Measles vaccine, however, has the potential to cause serious adverse events in immunocompromised persons due to replication of measles vaccine virus [5, 6] . Progressive HIVrelated immunosuppression can also impair vaccine effectiveness. In healthy immunocompetent persons, adverse events after measles vaccination are usually mild and transient, and seroconversion rates of .90% can be achieved [7, 8] .
The World Health Organization (WHO) recommended in 2004 that, unless severely immunocompromised, HIV-infected infants should receive measles vaccine at 6 months of age, followed by another dose at 9 months [8] . In practice, this is difficult to achieve because the child's HIV infection status is usually unknown during early infancy [3] . The WHO Global Advisory Committee on Vaccine Safety (GACVS) subgroup on immune deficiencies commissioned this systematic review and contributed to formulating research questions to reassess current recommendations. The objective was to examine the safety and immunogenicity of measles vaccine in HIV-1-infected children to assess the balance of benefits and risks.
METHODS

Information Sources and Search
We searched Medline, Embase, the Cochrane Library, African Index Medicus, the Indian Medlars Centre, Latin American and Caribbean Health Sciences, AIDSLine, and Conference on Retroviruses and Opportunistic Infections abstracts for articles published from the earliest date available through February 2009. We used key words or subject headings for ''measles vaccine'' or ''measles immunization'' in combination with ''HIV,'' adapted to each database. We screened bibliographies of selected review articles and contacted experts to identify additional publications or studies. There were no language restrictions.
Eligibility Criteria
Eligible study designs were randomized controlled trials (RCTs) or quasi-RCTs, controlled clinical trials, cohort, case-control, or cross-sectional studies, comparing measles-vaccinated HIVinfected children with measles-vaccinated HIV-uninfected children (either HIV-unexposed or HIV-exposed but uninfected) or HIV-infected children not vaccinated against measles. To assess safety, we also considered case reports that might identify rare adverse events and studies of measles vaccination of HIV-infected children without a comparison group.
The population of interest was children 0-15 years of age, either with confirmed HIV-1 infection or who were exposed to HIV-1 (ie, born to an HIV-1-infected mother) with or without confirmed infection. The intervention was measles vaccination with a licensed, single-or combined-antigen vaccine. Outcomes relating to vaccine safety, immunogenicity, or clinical measles were required to be reported. Studies meeting all criteria were included.
Study Selection
Two reviewers (PS and NL) independently evaluated all retrieved articles sequentially by title, abstract, and full text. Those considered by one or both reviewers to potentially match inclusion criteria were retained at each stage.
Data Collection and Analysis
Two reviewers (PS and ZG) independently extracted data onto piloted structured forms, including information on study population, vaccine types, sample size, loss to follow-up, outcomes, and source of funding. We also extracted information about predefined study characteristics that could result in bias, such as loss to follow-up, lack of blinding in the assessment of outcomes, or differences between groups in the interval between vaccination and serological assessment.
We assessed whether safety outcomes were reported and numbers and types of serious adverse events, including deaths. For measles vaccine immunogenicity, we extracted data on laboratory assays and definitions of serological responses, as well as results. Most studies reported seropositivity after vaccination, but some reported seroconversion (change from seronegative to seropositive or 4-fold increase in titer). We therefore used a composite outcome for serological response, using seropositivity when available and seroconversion otherwise, based on definitions provided by the authors. We considered children to be HIV infected if they met the definition for HIV infection used in the study in which they participated. Data were entered in EpiData (EpiData Association) by each of the reviewers. Discrepancies were resolved by consensus, with a third reviewer (NL) acting as arbiter.
We calculated the percentage seropositive with exact binomial 95% confidence intervals (CIs) separately for each comparison group in each study and displayed these in forest plots. Serological responses in HIV-infected children were compared with those of available comparison groups in each study with use of relative risks (RRs) and 95% CIs. Data were combined, when appropriate, using DerSimonian and Laird random-effects meta-analysis [9] . We quantified between-trial heterogeneity with use of the I 2 statistic [10] . Meta-analysis was considered to be inappropriate when the I 2 statistic exceeded 50% or a single study contributed to $2 estimates within strata. Between-trial heterogeneity was first explored by stratifying results by age at vaccination (6 months, 9 months, and $12 months) and then examining heterogeneity within strata. Forest plots of study results were also stratified by serological cutoff point, serological test, interval between vaccination and serology, and receipt of highly active antiretroviral therapy (HAART), and variation between results was assessed visually. Detailed exploration of heterogeneity by meta-regression was not possible because data from 1 study that involved vaccination at different ages [11] would have appeared multiple times. Differences between the results of small and large comparative trials were assessed by visual inspection of funnel plots and with a statistical test for asymmetry [12] for outcomes reported by $10 trials. Analyses were conducted using Stata, version 10 (StataCorp). The study protocol, search strategy, and criteria for the assessment of the risk of bias are available on request from the authors.
RESULTS
Description of Studies Included
The searches identified 723 potentially relevant articles ( Figure 1 ). Most ineligible studies were excluded on the basis of information in the title or abstract. We included 39 articles published from 1989 through 2008 in the review (Table 1 ). There were 23 articles with comparison groups that reported data from 25 separate study populations. All reported on immunogenicity [11, 13, 19-25, 29-33, 36, 37, 39, 42, 45-49] , and 10 (11 study populations) reported on adverse events [11, 23, 24, 25, 30, 36, 37, 39, 42, 47] (Figure 1 ). In total, 4520 children in comparative studies were vaccinated against measles. Of these, 716 were HIV infected, 1312 were HIV exposed but uninfected, and 1632 were HIV unexposed. There were 860 vaccinated children in 2 studies in which the numbers vaccinated in each comparison group were not provided [23, 39] . Twenty-three studies were available for examining the comparison of serological responses in measlesvaccinated HIV-infected children with measles-vaccinated HIV-uninfected children (either HIV unexposed or HIV exposed but uninfected) [11, 13, 20, 21, 23-25, 29-33, 36, 37, 39, 42, 45-49] . Two of these studies also included a comparison between measles-vaccinated HIV-infected children and HIVinfected children either not vaccinated or not revaccinated against measles [29, 36] . In addition, 1 study restricted to HIVinfected children compared vaccination at 6 and 12 months with vaccination at 12 months only [22] , and 1 study compared seroconversion in HIV-infected children receiving or not receiving HAART [19] .
Noncomparative studies examining only HIV-infected children were included in the assessment of measles vaccine safety ( Figure 1 ). We included 15 articles (reporting data from 11 studies) published from 1987 thtough 2008 [14-18, 26-28, 34, 35, 38, 40, 41, 43, 44] and data reported from 2 of the comparative studies that involved prospective revaccination of only HIV-infected children (referred to as substudies) [33, 45] . These 13 studies involved at least 515 measles-vaccinated HIVinfected children [14, 16-18, 26 27, 33-35 38 40 43 45] , because the number vaccinated was unclear in 2 studies [40, 43] . We also included a case report of a child in the United Kingdom in the assessment of measles vaccine safety only [6] .
Potential for Bias
There were 7 prospective cohort studies [11, 23, 29, 30, 37, 39, 47] , 12 cross-sectional or retrospective cohort studies [13, 19, 20, 24, 31-33, 36, 45, 46, 48,49] , and 1 RCT [22] . The study design in 5 studies (reported in 3 articles) was not clear [21, 25, 42] . In prospective studies and the RCT, 44%-100% of vaccinated children contributed to the immunogenicity analyses, with .75% contributing in 5 studies [11, 22, 29, 37, 47] . Only 3 of 25 studies reported blinding in the assessment of outcomes related to either the children's HIV infection or vaccination status [23, 30, 31] . The interval between vaccination and serological assessment was reported to be similar between groups in only 2 studies [31, 48] ; in 7 studies, the interval was not reported but was likely to be similar [11, 23, 29, 30, 42, 45, 47] . Details of all items assessed can be seen in Supplementary Table 1 .
Smaller trials tended to show lower serological responses than larger trials in HIV-infected children, compared with HIVexposed but uninfected children (P 5 .015 from test for funnel plot asymmetry in the only comparison containing .10 trials). This finding persisted in studies in which children were vaccinated at 9 months (8 studies; P 5 .019) but not in which children were vaccinated at 6 months (3 studies; P 5 .308) or $12 months (5 studies; P 5 .442) of age.
Measles Vaccine Safety
More than 1200 HIV-infected measles-vaccinated children were included in 39 comparative and noncomparative studies assessed for adverse events (number unclear in 6 studies [23, 25, 32, 39, 40, 43] ). We did not identify any study that explicitly reported measles inclusion body encephalitis, giant cell pneumonia, or thrombocytopenia in an HIV-infected child. Only 19 studies, involving at least 630 children, made explicit reference to adverse events ( Table 2 ). In 7 studies, there was an explicit statement about the absence of adverse events in HIV-infected children [17, 24, 25, 26, 27, 33, 38] . Seven studies had similar statements but also reported results that made interpretation difficult (eg, that hospitalizations or deaths occurred among study children) [23, 30, 36, 40, 42, 47] . The remaining 5 studies reported that deaths or other serious adverse events occurred among study children [6, 11, 34, 37, 39] . a Groups: 1, HIV-infected (vaccinated); 2, HIV-unexposed (vaccinated); 3, HIV-exposed but uninfected (vaccinated); 4, other; S Safety outcomes: S 0 , no adverse event information reported; S 1 , explicit reporting on adverse events; S 2 , explicit reporting on serious adverse events; S 2 *, information based on 'adverse event statement'; S 3 , information on deaths reported; P Progression of HIV: P 1 , information on progression of HIV-related disease reported; I Immunogenicity outcomes: I 0 , immunogenicity either not reported or not assessed in this review; I 1 , seropositivity after vaccination reported; I 2 , seroconversion (seronegative before vaccination, seropositive after) reported; I 3 , seroconversion (4-fold rise in titer) reported; I 4 , measure which might either be seropositivity after vaccination or seroconversion (seronegative before vaccination, seropositive after) is reported; I 5 summary immunological measure (e.g. geometric mean titer) reported for each group;
Deaths after vaccination were reported in 7 studies [11, 23, 30, 34, 37, 40, 47] . No study stated that any deaths were related to measles vaccination. In 1 study, it was stated that ''no excess of.death was found in association with vaccination'' [39, p31] . The child described in the case report survived [6] . At least 75 deaths were reported among vaccinated HIV-infected children (in 1 study, the number reported included unvaccinated children).
Details about hospitalizations were infrequently reported, although 2 large prospective studies involving 1298 vaccinated children reported that no hospitalizations were considered to be measles vaccine related [11, 37] . One study reported a retrospective search for adverse events in the study cohort of 221 vaccinated children [34] . No serious adverse events were documented, and no cases of measles vaccine-related encephalitis were reported to the regional authority during the period under review. We found no studies directly comparing hospitalization rates in vaccinated and unvaccinated HIV-infected children. There was only 1 report of a serious adverse event potentially associated with measles vaccination in which receipt of measles vaccine could be confirmed. This was a nonfatal illness resembling measles after vaccination of a 14-month-old boy, in whom measles vaccine virus was sequenced from a peripheral blood sample [6] .
Measles Vaccine Immunogenicity
The majority of studies used enzyme-linked immunoassays to determine measles antibody levels, but definitions and cutoff points varied across studies (Figures 2-4) . Two studies used high-titer Edmonston-Zagreb vaccine, defined as potencies .4.7 log 10 in children vaccinated at 6 months of age [23, 30] . These studies were included, but we did not combine these results with those from studies using standard-titer measles vaccine.
HIV-Infected Children. Levels of serological response among HIV-infected children varied between studies, but there was no clear pattern according to age at primary vaccination ( Figure 2 ). One study examined vaccination with standard-titer measles vaccine at 6 and 9 months of age [11] ; 59% (95% CI, 46%-71%) of children were seropositive after measles vaccination at 6 month of age, and 64% (95% CI, 49%-78%) were seropositive after measles vaccination at 9 months of age. These findings were consistent with results from 6 of 7 other studies of HIV-infected children receiving primary measles vaccination at 9 months of age. After vaccination at $12 months of age, point estimates ranged from 21% to 100%. No single factor (eg, serological cutoff point, serological test used, and interval between vaccination and serology or receipt of HAART) appeared to account for the variation between studies of vaccination at 9 or 12 months of age.
HIV-Exposed but Uninfected Children. Seropositivity after vaccination with standard-titer measles vaccine at 6 months was 68% (95% CI, 62%-74%) [11] . After vaccination at 9 months of age, point estimates of the proportion of seropositive children ranged from 62% to 100% and were $90% in 4 of 8 studies (Figure 3 ). After vaccination at 12 months of age, the proportion of seropositive HIV-exposed but uninfected children was .90% in all studies.
HIV-Unexposed Children. The pattern of serological response by age at measles vaccination in HIV-unexposed children was similar to that observed among HIV-exposed but uninfected children (Figures 3 and 4) . Nine studies included a comparison group of HIV-unexposed children (Figure 4 ). In the only study using standard-titer measles vaccine at 6 months of age, 62% (95% CI, 57%-66%) of children became seropositive [11] . The proportion of seropositive children was higher after measles vaccination at 9 months and was 100% after vaccination at 12 months in 2 small studies.
Comparisons Between Groups, According to HIV Infection Status
In the only study using standard-titer measles vaccine at 6 months of age [11] , there was no statistical evidence of a difference in serological response rates between HIV-infected and children who were either HIV-exposed but uninfected or HIVunexposed (Table 3) .
There were 2 studies that examined the effects of high-titer measles vaccine given at 6 months of age [23, 30] . In HIVinfected children in these studies, serological responses were slightly higher than those in the study that used standard-titer vaccine [11] (Figure 2) . In comparative analyses, the serological response after vaccination with standard-titer vaccine at 6 months of age in HIV-exposed but uninfected children was slightly greater than in HIV-unexposed children (RR, 1.11; 95% CI, .99-1.24) [11] , with similar results in high-titer studies [23, 30] .
After vaccination at 9 months, serological responses in HIVexposed but uninfected and HIV-unexposed groups were similar (Table 3 ). Comparisons between HIV-infected and HIV-exposed but uninfected children showed lower levels of seropositivity in HIV-infected children at 12 months (RR, 0.61; 95% CI, .50-.73) [11] . No studies of children vaccinated at $12 months of age reported a comparison between HIVexposed but uninfected and HIV-unexposed children.
Comparisons Between HIV-Infected Children, According to Antiretroviral Therapy
We found 2 studies that assessed the impact of antiretroviral therapy on serological responses to measles vaccine. Berkelhamer et al [19] examined HIV-infected children who had previously received measles vaccine but had nonprotective antibody levels. Seroconversion after revaccination was compared between 14 children receiving HAART and 14 children who were not receiving HAART (data from untreated children and those receiving less potent regimens combined by authors). More children seroconverted who were receiving HAART than 
DISCUSSION
This systematic review synthesized published evidence about the safety and immunogenicity of measles vaccine in 39 studies involving .1200 HIV-infected children. No study reported deaths in HIV-infected children related to measles vaccine, and we found only 1 case report of a serious adverse event possibly related to measles vaccination. There was an absence of studies directly comparing vaccinated with unvaccinated HIV-infected children. Seropositivity after vaccination in HIV-infected children did not improve as age at vaccination increased, unlike in HIV-uninfected children.
The main strengths of our review were the systematic strategy and broad search terms used to identify studies in a wide range of databases and the rigorous methods used to extract and appraise the data. The main limitation of this review was the need to rely on observational data, apart from a small uncompleted RCT [22] . The potential for confounding and bias should therefore be considered when interpreting the results. There was some statistical evidence that smaller trials were more likely to show lower serological responses in HIV-infected children, compared with HIV-exposed but uninfected children, which could result from publication bias [12] . There might also be systematic differences between smaller and larger trials. Trials of children vaccinated at older ages tended to be smaller, and the funnel plot asymmetry persisted in the group of trials among children vaccinated at 9 months but not at 12 months. Differences in types of serological assay and definitions of protective levels were likely to affect the proportion of children seropositive after vaccination in the HIV-infected group. We could not assess these differences formally because of variability in the assays.
We did not find evidence that serious adverse events due to measles vaccination of HIV-infected children were common in studies reporting this outcome. Generally poor reporting of safety outcomes meant, however, that the incidence of adverse events could not be estimated with confidence. Furthermore, the sample sizes of prospective studies were insufficient to detect rare events. The lack of studies directly comparing vaccinated with unvaccinated HIV-infected children limited assessment of whether adverse events occurring after vaccination were in excess of the illnesses and deaths that would have occurred if these children had not been vaccinated. We identified a case report of a 14-month-old, HIV-infected boy who developed fever and rash after receiving measles-mumps-rubella vaccine that resolved after hospitalization without complications [6] ; however, up to 5% of healthy individuals may experience fever after measles vaccination and 2% may have a rash [3] . The only documented case of fatal disease associated with measles vaccine virus in an HIV-1-infected person was in a 20-year-old man in the United States who died 15 months after receiving his second dose of measles vaccine [5] . Ten months after measles vaccination, he developed a giant cell pneumonia and measles vaccine virus was identified in his lung.
In areas where measles virus is circulating [1] , HIV-infected and HIV-exposed but uninfected children could benefit from earlier vaccination. Children born to HIV-infected women become susceptible to measles virus infection at a younger age than do children of uninfected mothers [3] , because placental transfer of maternal antibodies is impaired in HIV-1-infected women where more than 75% of vaccinated children were available for immunogenicity analyses b Studies where blood was drawn for measles serology less than 6 months after vaccination [50] . Our findings suggest that measles vaccine could be given to all infants of HIV-infected mothers at 6 months, even if the child's HIV infection status is not known. Although only 1 study used standard-titer measles vaccine at this age, it was a large well-conducted prospective study [11] . Two studies using high-titer measles vaccine at 6 months of age produced results consistent with this pattern [23, 30] . Although this vaccine is no longer used, these studies provide supportive evidence of the immunogenicity of early measles vaccination in HIV-infected children. The level of seropositivity in HIV-infected children vaccinated at 6 months of age was comparable to that achieved in HIV-infected children receiving primary measles vaccination at 9 months in several other studies [32, 39, 42, 47] . In addition, the response to measles vaccine at 6 months among HIV-exposed but uninfected children was slightly higher than that in HIVunexposed children [11] . Lower levels of maternal antibody in HIV-exposed but uninfected children [50] might allow for a better immunological response to earlier doses of measles vaccine.
The results of this review have implications for measles control strategies in areas with a high prevalence of HIV infection. The 2009 WHO position paper on measles vaccination, supported by the results of this review, now states that the first dose of measles vaccine can be given as early as 6 months in areas where there is a high incidence of both measles and HIV infection [7] . This recommendation means that HIV infection status does not have to be known before early vaccination. There are opportunities to provide measles vaccine at 6 and 9 months to children of mothers who are known to be HIV infected and are receiving care in Prevention of Mother-To-Child Transmission Plus or antiretroviral treatment programs. Supplementary immunization activities and programs to accelerate coverage of routine measles vaccination would also increase levels of indirect protection to susceptible HIV-infected children. There are some priorities for both public health research and practice. Large studies of the effects of expanded access to HAART on susceptibility to measles and serological responses to measles vaccination should be conducted, and the assessment and reporting of measles vaccine safety need to be improved. In summary, measles vaccines appear to be safe in HIV-infected children, but evidence is limited. Because of the potentially increased case-fatality associated with measles in HIV-infected children, children of HIV-infected mothers may benefit from initial vaccination at 6 months in regions with high measles burden, regardless of the child's HIV status. 
